Original Article

You have full text access to this OnlineOpen article

Inflammatory breast cancer outcome with epirubicin-based induction and maintenance chemotherapy†

Ten-Year Results from the French Adjuvant Study Group GETIS 02 Trial

  1. Corinne Veyret MD1,‡,*,
  2. Christelle Levy MD2,
  3. Philippe Chollet PhD3,
  4. Yacine Merrouche PhD4,
  5. Henri Roche PhD5,
  6. Pierre Kerbrat PhD6,
  7. Pierre Fumoleau PhD7,
  8. Pierre Fargeot MD7,
  9. Pierre Clavere PhD8,
  10. Bernard Chevallier MD1,§

Article first published online: 19 OCT 2006

DOI: 10.1002/cncr.22227

Issue

Cancer

Cancer

Volume 107, Issue 11, pages 2535–2544, 1 December 2006

Additional Information

How to Cite

Veyret, C., Levy, C., Chollet, P., Merrouche, Y., Roche, H., Kerbrat, P., Fumoleau, P., Fargeot, P., Clavere, P. and Chevallier, B. (2006), Inflammatory breast cancer outcome with epirubicin-based induction and maintenance chemotherapy. Cancer, 107: 2535–2544. doi: 10.1002/cncr.22227

Author Information

  1. 1

    Department of Medical Oncology, Henri Becquerel Center, Rouen, France

  2. 2

    Department of Medical Oncology, Francois Baclesse Center, Caen, France

  3. 3

    Department of Medical Oncology, Jean Perrin Center, Clermont-Ferrand, France

  4. 4

    Department of Medical Oncology, Cancer Institute of the Loire, St-Etienne, France

  5. 5

    Department of Medical Oncology, Claudius Regaud Institute, Toulouse, France

  6. 6

    Department of Medical Oncology, Eugene Marquis Center, Rennes, France

  7. 7

    Department of Medical Oncology, Georges-Francois Leclerc Center, Dijon, France

  8. 8

    Department of Radiotherapy, Hospital Center of the University of Dupuytren, Limoges, France

  1. ‡

    Fax: (011) 33 232082501

  2. §

    Deceased.

*Department of Medical Oncology, Centre Henri Becquerel, Rue d'Amiens, 76038 Rouen Cedex 1, France

  1. †

    Presented as a poster (Abstract 506) at the 33rd Annual Meeting of the American Society of Clinical Oncology, Denver, Colorado, May 17–20, 1997.

Publication History

  1. Issue published online: 17 NOV 2006
  2. Article first published online: 19 OCT 2006
  3. Manuscript Accepted: 27 JUL 2006
  4. Manuscript Revised: 12 JUN 2006
  5. Manuscript Received: 3 APR 2006

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (164K)

REFERENCES

  • 1
    Levine PH, Steinhorn SC, Ries LG, et al. Inflammatory breast cancer: the experience of the Surveillance, Epidemiology, and End Results (SEER) Program. J Natl Cancer Inst. 1985; 74: 291–297.
  • 2
    Chang S, Parker SL, Pham T, et al. Inflammatory breast carcinoma incidence and survival: the Surveillance, Epidemiology, and End Results Program of the National Cancer Institute, 1975–1992. Cancer. 1998; 82: 2366–2372.
    Direct Link:
  • 3
    Jaiyesimi IA, Buzdar AU, Hortobagyi G. Inflammatory breast cancer: a review. J Clin Oncol. 1992; 10: 1014–1024.
  • 4
    Chevallier B, Bastit P, Graic Y, et al. The Centre H. Becquerel studies in inflammatory non metastatic breast cancer. Combined modality approach in 178 patients. Br J Cancer. 1993; 67: 594–601.
  • 5
    Ueno NT, Buzdar AU, Singletary SE, et al. Combined-modality treatment of inflammatory breast carcinoma: twenty years of experience at M. D. Anderson Cancer Center. Cancer Chemother Pharmacol. 1997; 40: 321–329.
  • 6
    Feldman LD, Hortobagyi GN, Buzdar AU, et al. Pathological assessment of response to induction chemotherapy in breast cancer. Cancer Res. 1986; 46: 2578–2581.
  • 7
    Maloisel F, Dufour P, Bergerat JP, et al. Results of initial doxorubicin, 5-fluorouracil, and cyclophosphamide combination chemotherapy for inflammatory carcinoma of the breast. Cancer. 1990; 65: 851–855.
    Direct Link:
  • 8
    Early Breast Cancer Trialists' Collaborative Group. Polychemotherapy for early breast cancer: an overview of the randomised trials. Lancet. 1998; 352: 930–942.
  • 9
    French Epirubicin Study Group. A prospective randomized Phase III trial comparing combination chemotherapy with cyclophosphamide, fluorouracil and either doxorubicin or epirubicin. J Clin Oncol. 1988; 6: 679–688.
  • 10
    Italian Multicentre Breast Study with Epirubicin. Phase III randomized study of fluorouracil, epirubicin, and cyclophosphamide v fluorouracil, doxorubicin, and cyclophosphamide in advanced breast cancer: an Italian multicentre trial. J Clin Oncol. 1988; 6: 976–982.
  • 11
    Gisselbrecht C, Lepage E, Extra JM, et al. Cancer of the breast: intensive treatment with bone marrow autografts. Bull Cancer. 1989; 76: 99–104.
  • 12
    Hansen R, Quebbeman E, Beatty P, et al. Continuous 5-fluorouracil infusion in refractory carcinoma of the breast. Breast Cancer Res Treat. 1987; 10: 145–149.
  • 13
    Chevallier B, Roche H, Olivier JP, et al. Inflammatory breast cancer. Pilot study of intensive induction chemotherapy (FEC-HD) results in a high histologic response rate. Am J Clin Oncol. 1993; 16: 223–228.
  • 14
    Chevallier B, Chollet P, Merrouche Y, et al. Lenograstim prevents morbidity from intensive induction chemotherapy in the treatment of inflammatory breast cancer. J Clin Oncol. 1995; 13: 1564–1571.
  • 15
    Snedecor GW, Cochran WG. Statistical methods. 7th ed. Ames: Iowa State University Press, 1980.
  • 16
    Duncan DB. P-tests and intervals for comparison suggested by the data. Biometrics. 1975; 31: 339–359.
  • 17
    Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1985; 53: 229–232.
  • 18
    Peto R, Peto J. Asymptotically efficient rank invariant test procedures. J R Stat Soc A. 1972; 135: 185–198.
  • 19
    Cox DR. Regression models and life-tables. J R Stat Soc B. 1972; 34: 187–202.
  • 20
    Harris EER, Schultz D, Bertsch H, et al. Ten-year outcome after combined modality therapy for inflammatory breast cancer. Int J Radiat Oncol Biol Phys. 2003; 55: 1200–1208.
  • 21
    Bauer RL, Busch E, Levine E, Edge SB. Therapy for inflammatory breast cancer: impact of doxorubicin-based therapy. Ann Surg Oncol. 1995; 2: 288–294.
  • 22
    Attia-Sobol J, Ferriere JP, Cure H, et al. Treatment results, survival and prognostic factors in 109 inflammatory breast cancers: univariate and multivariate analysis. Eur J Cancer. 1993; 29A: 1081–1088.
  • 23
    Palangie T, Mosseri V, Mihura J, et al. Prognostic factors in inflammatory breast cancer and therapeutic implications. Eur J Cancer. 1994; 30A: 921–927.
  • 24
    Colozza M, Gori S, Mosconi AM, et al. Induction chemotherapy with cisplatin, doxorubicin, and cyclophosphamide (CAP) in a combined modality approach for locally advanced and inflammatory breast cancer. Long-term results. Am J Clin Oncol. 1996; 19: 10–17.
  • 25
    Thomas F, Arriagada R, Spielmann M, et al. Pattern of failure in patients with inflammatory breast cancer treated by alternating radiotherapy and chemotherapy. Cancer. 1995; 76: 2286–2290.
    Direct Link:
  • 26
    Tubiana-Mathieu N, Lejeune C, Bonnier P, et al. Chemotherapy and concomitant irradiation in inflammatory breast cancer. Anticancer Res. 2001; 21: 3061–3067.
  • 27
    Brun B, Otmezguine Y, Feuilhade F, et al. Treatment of inflammatory breast cancer with combination chemotherapy and mastectomy versus breast conservation. Cancer. 1988; 61: 1096–1103.
    Direct Link:
  • 28
    Bertucci F, Tarpin C, Charafe-Jauffret E, et al. Multivariate analysis of survival in inflammatory breast cancer: impact of intensity of chemotherapy in multimodality treatment. Bone Marrow Transplant. 2004; 33: 913–920.
  • 29
    Arun B, Slack R, Gehan E, et al. Survival after autologous hematopoietic stem cell transplantation for patients with inflammatory breast carcinoma. Cancer. 1999; 85: 93–99.
    Direct Link:
  • 30
    Perez CA, Fields JN, Fracasso PM, et al. Management of locally advanced carcinoma of the breast. II. Inflammatory carcinoma. Cancer. 1994; 74( Suppl 1): 466–476.
    Direct Link:
  • 31
    De Boer RH, Allum WH, Ebbs SR, et al. Multimodality therapy in inflammatory breast cancer: is there a place for surgery? Ann Oncol. 2000; 11: 1147–1153.
  • 32
    Hagelberg RS, Jolly PC, Anderson RP. Role of surgery in the treatment of inflammatory breast carcinoma. Am J Surg. 1984; 148: 125–131.
  • 33
    Fleming RY, Asmar L, Buzdar AU, et al. Effectiveness of mastectomy by response to induction chemotherapy for control in inflammatory breast carcinoma. Ann Surg Oncol. 1997; 4: 452–461.
  • 34
    Thoms WWJr., McNeese MD, Fletcher GH, et al. Multimodal treatment for inflammatory breast cancer. Int J Radiat Oncol Biol Phys. 1989; 17: 739–745.
  • 35
    Arthur DW, Schmidt-Ullrich RK, Friedman RB, et al. Accelerated superfractionated radiotherapy for inflammatory breast carcinoma: complete response predicts outcome and allows for breast conservation. Int J Radiat Oncol Biol Phys. 1999; 44: 289–296.
  • 36
    Fein DA, Mendenhall NP, Marsh RD, et al. Results of multimodality therapy for inflammatory breast cancer: an analysis of clinical and treatment factors affecting outcome. Am Surg. 1994; 60: 220–225.
  • 37
    Giordano SH. Update on locally advanced breast cancer. Oncologist. 2003; 8: 521–530.
  • 38
    Ayash LJ, Elias A, Ibrahim J, et al. High-dose multimodality therapy with autologous stem-cell support for Stage IIIB breast carcinoma. J Clin Oncol. 1998; 16: 1000–1007.
  • 39
    Viens P, Palangie T, Janvier M, et al. First-line high-dose sequential chemotherapy with rG-CSF and repeated blood stem cell transplantation in untreated inflammatory breast cancer: toxicity and response (PEGASE 02 trial). Br J Cancer. 1999; 81: 449–456.
  • 40
    Cristofanilli M, Gonzalez-Angulo AM, Buzdar AU, et al. Paclitaxel improves the prognosis in estrogen receptor negative inflammatory breast cancer: the M. D. Anderson Cancer Center experience. Clin Breast Cancer. 2004; 4: 415–419.
  • 41
    Bear HD, Anderson S, Brown A, et al. The effect on tumor response of adding sequential preoperative docetaxel to preoperative doxorubicin and cyclophosphamide: preliminary results from National Surgical Adjuvant Breast and Bowel Project Protocol B-27. J Clin Oncol. 2003; 21: 4165–4174.
  • 42
    Hutcheon AW, Heys SD, Sarkar TK, et al. Docetaxel primary chemotherapy in breast cancer: a five year update of the Aberdeen trial [abstract 11]. 26th San Antonio Breast Cancer Symposium, San Antonio, Texas, December 3–6, 2003.
  • 43
    Pedersen-Bjergaard J, Philip P. Two different classes of therapy-related and de-novo acute myeloid leukemia? Cancer Genet Cytogenet. 1991; 55: 119–124.
  • 44
    Smith RE, Bryant J, DeCillis A, et al. Acute myeloid leukemia and myelodysplastic syndrome after doxorubicin-cyclophosphamide adjuvant therapy for operable breast cancer: the National Surgical Adjuvant Breast and Bowel Project experience. J Clin Oncol. 2003; 21: 1195–1204.
  • 45
    Bergh J, Wiklund T, Erikstein B, et al. Tailored fluorouracil, epirubicin, and cyclophosphamide compared with marrow-supported high-dose chemotherapy as adjuvant treatment for high-risk breast cancer: a randomised trial. Scandinavian Breast Group 9401 study. Lancet. 2000; 356: 1384–1391.
  • 46
    Aziz SA, Pervez S, Khan S, et al. Case control study of prognostic markers and disease outcome in inflammatory carcinoma breast: a unique clinical experience. Breast J. 2001; 7: 398–404.
    Direct Link:
  • 47
    Mayo LD, Donner DB. The PTEN, Mdm2, p53 tumor suppressor-oncoprotein network. Trends Biochem Sci. 2002; 27: 462–467.
  • 48
    van Golen KL, Wu ZF, Qiao XT, et al. RhoC GTPase, a novel transforming oncogene for human mammary epithelial cells that partially recapitulates the inflammatory breast cancer phenotype. Cancer Res. 2000; 60: 5832–5838.
  • 49
    van Golen KL, Bao L, DiVito MM, et al. Reversion of RhoC GTPase-induced inflammatory breast cancer phenotype by treatment with a farnesyl transferase inhibitor. Mol Cancer Ther. 2002; 1: 575–583.
View Full Article (HTML) Get PDF (164K)